SlideShare una empresa de Scribd logo
1 de 59
This presentation is compiled by “ Drug Regulations” a
non profit organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
3/28/2015 1
This presentation is compiled from freely available
resources like the website of MHRA , specifically
“MHRA GMP Data Integrity Definitions and
Guidance for Industry March 2015”
“Drug Regulations” is a non profit organization
which provides free online resource to the
Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
3/28/2015 2
Drug Regulations : Online
Resource for Latest Information
 Data integrity
◦ Fundamental in a pharmaceutical quality system
◦ Ensures that medicines are of required quality
◦ This presentation is based on MHRA Guidance
◦ Provides MHRA expectations
◦ Guidance complements existing EU GMP relating to active
substances and dosage forms
◦ To be used in conjunction with national medicines legislation and
the GMP standards published in Eudralex volume 4.
3/28/2015 3Drug Regulations : Online Resource for Latest Information
 Make data governance integral part of pharmaceutical quality
system
 Provide resources commensurate with the risk to product quality
 Forensic approach to data checking is not required on routine
basis
 Design and operate a system which provides an acceptable state
of control
 This should be based on the data integrity risk
 Document with supporting rationale
3/28/2015 4Drug Regulations : Online Resource for Latest Information
 Data integrity requirements apply equally to
manual (paper) and electronic data.
 Do not revert from automated / computerised
to manual / paper-based systems
 This will not remove the need for data
integrity controls.
3/28/2015 5Drug Regulations : Online Resource for Latest Information
 If you do this
 It may also constitute a failure to comply with Article
23 of Directive 2001/83/EC,
 This article requires an authorisation holder to take
account of
◦ Scientific and technical progress and
◦ Enable the medicinal product to be manufactured and
checked by means of generally accepted scientific methods.
3/28/2015 6Drug Regulations : Online Resource for Latest Information
 Have an overarching data governance system
 Include relevant policies and staff training including the
importance of data integrity
 Consider the organisational (e.g. procedures) controls applied to
quality systems
 Consider technical (e.g. computer system access) controls
applied to quality systems
 Ensure that resources applied are commensurate with impact to
product quality attributes.
3/28/2015 7Drug Regulations : Online Resource for Latest Information
 Data may be generated by
◦ A paper-based record of a manual observation
◦ Equipment or computerized
 A spectrum of simple machines
 From complex highly configurable computerised
systems.
3/28/2015 8Drug Regulations : Online Resource for Latest Information
 Inherent data integrity risk
◦ Depends upon the extent to which system
generating or using the data can be
configured
◦ These systems can be potentially manipulated
 See next figure
3/28/2015 9Drug Regulations : Online Resource for Latest Information
Diagram to illustrate the spectrum of simple machine (left) to complex computerised
system (right), and Relevance of printouts as ‘original data’
3/28/2015 10Drug Regulations : Online Resource for Latest Information
 Simple systems
◦ pH meters and balances
◦ May only require calibration
 Complex systems
◦ Require ‘validation for intended purpose’.
 Validation effort increases from left to right in
the diagram above.
3/28/2015 11Drug Regulations : Online Resource for Latest Information
 Systems of apparent lower complexity may be
overlooked
◦ Possible to manipulate data
◦ Repeat testing to achieve a desired outcome possible
◦ Limited opportunity of detection
 Stand-alone systems with a user configurable output such as
FT-IR, UV spectrophotometers
3/28/2015 12Drug Regulations : Online Resource for Latest Information
 Design systems to encourage compliance with the
principles of data integrity. Ensure
◦ Access to clocks for recording timed events
◦ Accessibility to batch records at locations where activities
take place so that ad hoc data recording and later
transcription to official records is not necessary
◦ Control over blank paper templates for data recording
◦ User access rights which prevent (or audit trail) data
amendments
3/28/2015 13Drug Regulations : Online Resource for Latest Information
 Design systems to encourage compliance with
the principles of data integrity. Ensure
◦ Automated data capture or printers are attached to
equipment such as balances
◦ Proximity of printers to relevant activities
◦ Access to sampling points (e.g. for water systems)
◦ Access to raw data for staff performing data checking
activities.
3/28/2015 14Drug Regulations : Online Resource for Latest Information
 Use of scribes
◦ May be used to record activity on behalf of another operator
◦ Exceptional
◦ May be used only under following circumstances
 Act of recording places the product or activity at risk
 e.g. documenting line interventions by sterile operators.
◦ To accommodate cultural or staff literacy / language limitations
 Where an activity is performed by an operator, but witnessed and
recorded by a Supervisor or Officer.
3/28/2015 15
Drug Regulations : Online Resource for Latest Information
 Use of scribes
◦ In both situations,
 Supervisory recording must be contemporaneous with
the task being performed
 Must identify both the person performing the observed
task and the person completing the record.
3/28/2015 16
Drug Regulations : Online Resource for Latest Information
 Use of scribes
◦ In both situations,
 The person performing the observed task should
countersign the record wherever possible,
 although it is accepted that this countersigning step will be
retrospective.
 Describe supervisory (scribe) documentation completion in
an approved procedure
 Specify the activities to which the process applies
3/28/2015 17
Drug Regulations : Online Resource for Latest Information
Term Data
Definition Information derived or obtained from raw data (e.g. a
reported analytical result)
Expectation
or
Guidance
Data must be:
A - attributable to the person generating the data
L – legible and permanent
C – contemporaneous
O – original record (or ‘true copy’)
A - accurate
3/28/2015 18
Drug Regulations : Online Resource for Latest Information
Term Raw data
Definition • Original records and documentation, retained in the format in
which they were originally generated (i.e. paper or electronic),
or as a ‘true copy’.
• Raw data must be contemporaneously and accurately recorded
by permanent means.
• In the case of basic electronic equipment which does not store
electronic data, or provides only a printed data output (e.g.
balance or pH meter), the printout constitutes the raw data.
Expectation
or
Guidance
Raw data must:
• Be legible and accessible throughout the data lifecycle.
• Permit the full reconstruction of the activities resulting in the
generation of the data
3/28/2015 19
Drug Regulations : Online Resource for Latest Information
Term Metadata:
Definition • Data that describes the attributes of other data, and provide
context and meaning.
• Typically, these are data that describe the structure, data
elements, interrelationships and other characteristics of data.
• Permits data to be attributable to an individual.
Expectation
or
Guidance
Example:
• Data : e.g. 3.5
• Metadata, giving context and meaning, are:
• sodium chloride batch 1234, 3.5mg. J Smith 01/07/14
• Metadata forms an integral part of the original record.
• Without metadata, the data has no meaning.
3/28/2015 20
Drug Regulations : Online Resource for Latest Information
Term Data Integrity
Definition The extent to which all data are
• Complete
• Consistent
• Accurate throughout the data lifecycle.
Expectation
or
Guidance
Data integrity arrangements must ensure that the
• Accuracy
• Completeness
• Content meaning of data is retained throughout the data
lifecycle.
3/28/2015 21
Drug Regulations : Online Resource for Latest Information
Term Data governance
Definition The sum total of arrangements to ensure that data,
irrespective of the format in which it is generated, is
recorded, processed, retained and used to ensure a
complete, consistent and accurate record throughout the
data lifecycle
Expectation
or
Guidance
Data governance should address
• Data ownership throughout the lifecycle
• Design, operation and monitoring of processes / systems in
order to comply with the principles of data integrity
• Control over intentional and unintentional changes to
information.
3/28/2015 22
Drug Regulations : Online Resource for Latest Information
Term Data governance
Expectation
or
Guidance
Data Governance systems should include
• Staff training in the importance of data integrity principles
• Creation of a working environment that encourages an open
reporting culture for errors, omissions and aberrant results.
Senior management should be responsible for
• Implementation of systems and procedures to minimise the
potential risk to data integrity
• Identifying the residual risk, using the principles of ICH Q9.
• Contract givers to perform a similar review as part of their
vendor assurance programme
3/28/2015 23
Drug Regulations : Online Resource for Latest Information
Term Data Lifecycle
Definition • All phases in the life of the data
• Including raw data
• From initial generation and recording through processing
(including transformation or migration), use, data retention,
archive / retrieval and destruction.
Expectation
or
Guidance
• Procedures for destruction should consider data criticality and
legislative retention requirements.
• Archival arrangements should be in place for long term retention
• Some cases, periods up to 30 years) for records such as batch
documents, marketing authorisation application data, traceability data
for human-derived starting materials (not an exhaustive list).
• Additionally, at least 2 years of data must be retrievable in a timely
manner for the purposes of regulatory inspection.
3/28/2015 24
Drug Regulations : Online Resource for Latest Information
Term Primary Record
Definition • The record which takes primacy in cases where data that are
collected and retained concurrently by more than one method
fail to concur.
Expectation
or
Guidance
• In situations where the same information is recorded
concurrently by more than one system, the data owner should
define which system generates and retains the primary record,
in case of discrepancy.
• The ‘primary record’ attribute should be defined in the quality
system
• Attribute should not be changed on a case by case basis.
3/28/2015 25
Drug Regulations : Online Resource for Latest Information
Term Primary Record
Expectation
or
Guidance
• Use Risk management principles to ensure that the assigned
‘primary record’ provides the greatest accuracy, completeness,
content and meaning.
• Not appropriate for low-resolution or static (printed / manual)
data to be designated as a primary record in preference to
high resolution or dynamic (electronic) data.
• All data should be considered when performing a risk based
investigation into data anomalies (e.g. out of specification
results)
3/28/2015 26
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Definition • Original record:
• Data as the file or format in which it was originally generated,
preserving the integrity (accuracy, completeness, content and
meaning) of the record,
• e.g. original paper record of manual observation, or electronic
raw data file from a computerised system
• True Copy:
• An exact verified copy of an original record.
• Data may be static (e.g. a ‘fixed’ record such as paper or pdf)
or
• Dynamic (e.g. an electronic record which the user / reviewer
can interact with).
3/28/2015 27
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Definition • Example 1:
• A group of still images (photographs – the static ‘paper
copy’ example) may not provide the full content and
meaning of the same event as a recorded moving image
(video – the dynamic ‘electronic record’ example).
3/28/2015 28
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Definition • Example 2:
• Once printed or converted to static .pdfs, chromatography
records lose the capability of being reprocessed
• Do not enable more detailed viewing of baselines or any
hidden fields.
• By comparison, the same dynamic electronic records in
database format provides the ability to track, trend, and
query data,
• Allows the reviewer (with proper access permissions) to
reprocess, view hidden fields, and expand the baseline to
view the integration more clearly.
3/28/2015 29
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Expectation
or
Guidance
• Original records and true copies must preserve the integrity
(accuracy, completeness, content and meaning) of the record.
• Exact (true) copies of original records may be retained in place
of the original record (e.g. scan of a paper record),
• Put in place a documented system to verify and record the
integrity of the copy.
3/28/2015 30
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Expectation
or
Guidance
• Raw data generated by electronic means may be retained in
an acceptable paper or pdf format. For this
1. Justify how a static record maintains the integrity of the
original data.
2. Data retention process must be shown to include
• Verified copies of all raw data, metadata, relevant audit trail
and result files,
• Software / system configuration settings specific to each
analytical run*, and
• All data processing runs (including methods and audit trails)
necessary for reconstruction of a given raw data set.
3/28/2015 31
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Expectation
or
Guidance
• Raw data generated by electronic means may be retained in
an acceptable paper or pdf format. For this
3. Ensure a documented means to verify that the printed records
were an accurate representation.
• Onerous approach in its administration to enable a GMP
compliant record.
• Many electronic records are important to retain in their
dynamic (electronic) format, to enable interaction with the
data.
• Data must be retained in a dynamic form where this is critical
to its integrity or later verification.
• This should be justified based on risk.
3/28/2015 32
Drug Regulations : Online Resource for Latest Information
Term Original record / True Copy:
Expectation
or
Guidance
• Define , test , lock & protect computerised system
configuration settings from unauthorised access as part of
computer system validation.
• Only those variable settings which relate to an analytical run
would be considered as electronic raw data.
3/28/2015 33
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Definition • A computer system transaction is
1. A single operation or
2. Sequence of operations performed as a single logical ‘unit
of work’.
• The operation(s) that make up a transaction may not be
saved as a permanent record on durable storage until
1. User commits the transaction through a deliberate act
(e.g. pressing a save button), or
2. The system forces the saving of data
• The metadata (i.e., user name, date, and time) is not
captured in the system audit trail until the user commits
the transaction.
3/28/2015 34
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Definition • In Manufacturing Execution Systems (MES), an electronic
signature is often required by the system in order for the
record to be saved and become permanent.
3/28/2015 35
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Expectation
or
Guidance
• Computer systems should be designed to ensure that
1. Execution of critical operations are recorded
contemporaneously by the user
2. Not combined into a single computer system transaction with
other operations.
3. A critical processing step is a parameter that must be within
an appropriate limit, range, or distribution to ensure the
desired product quality.
4. These should be reflected in the process control strategy.
3/28/2015 36
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Expectation
or
Guidance
• Examples of 'units of work':
1. Weighing of individual materials
2. Entry of process critical manufacturing / analytical parameters
3. Verification of the identity of each component or material that
will be used in a batch
3/28/2015 37
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Expectation
or
Guidance
4. Verification of the addition of each individual raw material to
a batch (e.g. when the sequence of addition is considered
critical to process control
3/28/2015 38
Drug Regulations : Online Resource for Latest Information
Term Computer system transactions:
Expectation
or
Guidance
5. Addition of multiple pre-weighed raw materials to bulk vessel when
required as a single manufacturing step (e.g. when the sequence of
addition is not considered critical to process control
3/28/2015 39
Drug Regulations : Online Resource for Latest Information
Term Audit Trail
Definition • GMP audit trails are metadata that are a record of GMP critical
information
• (for example the change or deletion of GMP relevant data),
• They permit the reconstruction of GMP activities.
Expectation
or
Guidance
• Where computerised systems are used to capture, process, report
or store raw data electronically System design should
1. Always provide for the retention of full audit trails to show all
changes to the data
2. Retain previous and original data.
3. Associate all changes to data with the persons making those
changes,
4. Time stamp changes
5. Have a facility to Provide reason for change.
6. Not provide users the facility to amend or switch off the audit
trail.
40
Term Audit Trail
Expectation
or
Guidance
• Consider relevance of data retained in audit trails
• This should permit robust data review / verification.
• Should permit reconstruction of the process or activity.
• No need to include every system activity (e.g. user log on/off,
keystrokes etc.) in audit trail
• This may be achieved by review of designed and validated
system reports.
3/28/2015 41
Drug Regulations : Online Resource for Latest Information
Term Audit Trail
Expectation
or
Guidance
• Audit trail review
1. Part of the routine data review / approval process
2. Performed by the operational area which has generated the
data (e.g. laboratory).
3. Evidence to confirm that review of the relevant audit trails
have taken place.
4. Limited to those with GMP relevance (e.g. relating to data
creation, processing, modification and deletion etc).
5. Reviewed as a list of relevant data, or by a validated
‘exception reporting’ process.
6. Sample audit trail, raw data and metadata reviewed by QA to
ensure ongoing compliance
3/28/2015 42
Drug Regulations : Online Resource for Latest Information
Term Audit Trail
Expectation
or
Guidance
• System without audit trail
1. Have a paper based audit trail
2. Capable of demonstrating changes to data
3. Permitted until a fully audit trailed system becomes available.
4. Permitted, where they achieve equivalence to integrated audit
trail described in Annex 11 of the GMP Guide.
5. If equivalence cannot be demonstrated, it is expected that
facilities should upgrade to an audit trailed system by the end
of 2017.
3/28/2015 43
Drug Regulations : Online Resource for Latest Information
Term Data Review
Definition • Implement a procedure for review and approval of data,
including raw data.
• Include review of relevant metadata, data , including audit
trail.
Expectation
or
Guidance
Document Data Review
• Action to be taken if data review identifies an error or
omission should be specified in a procedure.
• Procedure should enable data corrections or clarifications to
be made in a GMP compliant manner
• Original record should be visible and audit trailed using
ALCOA principle
3/28/2015 44
Drug Regulations : Online Resource for Latest Information
Term Computerised system user access / system administrator
roles
Expectation
or
Guidance
Make full use of access controls
1. Ensure that people have access only to functionality that is
appropriate for their job role
2. Actions should be attributable to a specific individual
3. Demonstrate different access levels granted to individual staff
members
4. Ensure that historical information regarding user access level
is available
5. Do not use shared logins or generic user access
6. Where the computerised system design supports individual
user access, this function must be used.
7. This may require the purchase of additional licences.
3/28/2015 45
Drug Regulations : Online Resource for Latest Information
Term Computerised system user access / system administrator
roles
Expectation
or
Guidance
8. Some computerised systems support only a single user login
or limited numbers of user logins.
9. Upgrade to an appropriate system by the end of 2017 where
unique login is feasible.
10. Where no suitable alternative computerised system is
available, a paper based method of providing traceability is
permitted.
11. Justify & document the suitability of alternate system based
on a review of system design, and documented.
3/28/2015 46
Drug Regulations : Online Resource for Latest Information
Term Computerised system user access / system administrator
roles
Expectation
or
Guidance
12.Restrict system administrator access to the minimum number
of people possible
13.Consider the size and nature of the organisation for this.
14.Generic system administrator account should not be available
for use.
15. Personnel with system administrator access should log in
under unique log-ins
16.Ensure that all actions in the audit trail(s) are attributed to a
specific individual.
3/28/2015 47
Drug Regulations : Online Resource for Latest Information
Term Computerised system user access / system administrator
roles
Expectation
or
Guidance
17.Ensure that individual logs- in using account with appropriate
access rights for the given task
• Manager performing data checking should not log in as
system administrator
• System admistrator will have a more appropriate level of
access for that task.
3/28/2015 48
Drug Regulations : Online Resource for Latest Information
Term Data retention
Definition • Raw data generated in paper format may be retained for
example by scanning
• For copies there should be a process in place to ensure that
the copy is verified to ensure its completeness.
• Data retention may be classified as archive or backup
Expectation
or
Guidance
• Protect the records from deliberate or inadvertent alteration or
loss during retention.
• Place secure controls in place to ensure data Integrity of the
record throughout the retention period.
• Validate where appropriate.
3/28/2015 49
Drug Regulations : Online Resource for Latest Information
Term Data retention
Expectation
or
Guidance
• Contracted Data Retention
1. Specify the ownership and retrieval of data held under this
arrangement.
2. Consider physical location in which the data is held
3. Consider impact of any local laws applicable
4. Define responsibilities of the contract giver and acceptor as
described in Chapter 7 of the GMP Guide
3/28/2015 50
Drug Regulations : Online Resource for Latest Information
Term Archive
Definition • Long term, permanent retention of completed data and
relevant metadata in its final form for the purposes of
reconstruction of the process or activity.
Expectation
or
Guidance
• Lock records such that they cannot be altered or deleted
without detection and audit trail.
• Archive must permit recovery and readability of the data and
metadata throughout the required retention period.
3/28/2015 51
Drug Regulations : Online Resource for Latest Information
Term Backup
Definition • A copy of current (editable) data, metadata and system
configuration settings (variable settings which relate to an
analytical run) maintained for the purpose of disaster recovery.
Expectation
or
Guidance
• Backup and recovery processes must be validated
3/28/2015 52
Drug Regulations : Online Resource for Latest Information
Term File structure
Expectation
or
Guidance
• File structure has a significant impact on the inherent
data integrity risks.
• The ability to manipulate or delete flat files requires a
higher level of logical and procedural control over data
generation, review and storage.
3/28/2015 53
Drug Regulations : Online Resource for Latest Information
Term Flat files:
Definition • A 'flat file' is an individual record which may not carry with it
all relevant metadata (e.g. pdf, dat, doc ).
Expectation
or
Guidance
• Flat files may carry basic metadata relating to file
creation and date of last amendment,
• However they may not audit trail the type and sequence
of amendments.
• When creating flat file reports from electronic data, the
metadata and audit trails relating to the generation of
the raw data may be lost, unless these are retained as a
‘true copy’.
3/28/2015 54
Drug Regulations : Online Resource for Latest Information
Term Flat files:
Expectation
or
Guidance
• Consideration also needs to be given to the ‘dynamic’
nature of the data, where appropriate (see ‘true copy’
definition)
• There is an inherently greater data integrity risk with
flat files (e.g. when compared to data contained within
a relational database), in that these are easier to
manipulate and delete as a single file.
3/28/2015 55
Drug Regulations : Online Resource for Latest Information
Term Relational database:
Definition • A relational database stores different components of
associated data and metadata in different places.
• Each individual record is created and retrieved by compiling
the data and metadata for review
Expectation
or
Guidance
• File structure is inherently more secure
• Data is held in a large file format
• Preserves the relationship between data and metadata.
• More resilient to attempts to selectively delete, amend or
recreate data and the metadata trail of actions, compared to a
flat file system.
• Retrieval of information requires a database search tool, or the
original application which created the record.
3/28/2015 56
Drug Regulations : Online Resource for Latest Information
Term Validation - for intended purpose (See also Annex 15 and GAMP 5)
Expectation
or
Guidance
• Computerised systems
1. Must comply with the requirements of EU GMP Annex 11
2. Be validated for their intended purpose.
3. Understand the computerised system's function within a
process.
4. Acceptance of vendor-supplied validation data in isolation of
system configuration and intended use is not acceptable.
5. In isolation from the intended process or end user IT
infrastructure, vendor testing is likely to be limited to functional
verification only
6. This may not fulfil the requirements for performance
qualification.
3/28/2015 57
Drug Regulations : Online Resource for Latest Information
Term Validation - for intended purpose (See also Annex 15 and GAMP 5)
Expectation
or
Guidance
For example –
validation of computerised system audit trail
• A custom report generated from a relational database may be
used as a GMP system audit trail.
• SOPs should be drafted during OQ to describe the process for
audit trail verification, including definition of the data to be
reviewed.
• 'Validation for intended use' would include testing during PQ to
confirm that the required data is correctly extracted by the
custom report, and presented in a manner which is aligned with
the data review process described in the SOP.
3/28/2015 58
Drug Regulations : Online Resource for Latest Information
This presentation is compiled from freely available
resources like the website of EMA , specifically
“MHRA GMP Data Integrity Definitions and
Guidance for Industry March 2015”
“Drug Regulations” is a non profit organization
which provides free online resource to the
Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
3/28/2015 59
Drug Regulations : Online
Resource for Latest Information

Más contenido relacionado

La actualidad más candente

New WHO Guidance on Process Validation
New WHO Guidance on Process ValidationNew WHO Guidance on Process Validation
New WHO Guidance on Process Validation
GMP EDUCATION : Not for Profit Organization
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
Vidyasagar P
 

La actualidad más candente (20)

Data Integrity Training by Dr. A. Amsavel
Data Integrity Training   by Dr. A. AmsavelData Integrity Training   by Dr. A. Amsavel
Data Integrity Training by Dr. A. Amsavel
 
New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.New PICS Guidance on Data Integrity and Management.
New PICS Guidance on Data Integrity and Management.
 
Handling of Out of Specification Results
Handling of Out of Specification ResultsHandling of Out of Specification Results
Handling of Out of Specification Results
 
New WHO Guidance on Process Validation
New WHO Guidance on Process ValidationNew WHO Guidance on Process Validation
New WHO Guidance on Process Validation
 
21 CFR PART 11
21 CFR PART 1121 CFR PART 11
21 CFR PART 11
 
Ensuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environmentEnsuring data integrity in pharmaceutical environment
Ensuring data integrity in pharmaceutical environment
 
Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry Data integrity in Pharmaceutical industry
Data integrity in Pharmaceutical industry
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 
Data Integrity in FDA Regulated Labs
Data Integrity in FDA Regulated LabsData Integrity in FDA Regulated Labs
Data Integrity in FDA Regulated Labs
 
Data Integrity
Data IntegrityData Integrity
Data Integrity
 
Pharma data integrity
Pharma data integrityPharma data integrity
Pharma data integrity
 
Deviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADeviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPA
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
 
GMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICESGMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICES
 
CASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROLCASE STUDY ON CHANGE CONTROL
CASE STUDY ON CHANGE CONTROL
 
Review of Quality Control Record and Analytical Data by Dr. A. Amsavel
Review of  Quality Control Record and Analytical Data by Dr. A. AmsavelReview of  Quality Control Record and Analytical Data by Dr. A. Amsavel
Review of Quality Control Record and Analytical Data by Dr. A. Amsavel
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
 
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
 
Data Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality IntegrationData Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality Integration
 

Destacado

Destacado (10)

MHRA
MHRAMHRA
MHRA
 
TGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCATGA, MHRA, MCC, MCA
TGA, MHRA, MCC, MCA
 
Regulatory agency
Regulatory agencyRegulatory agency
Regulatory agency
 
Therapeutic good administration
Therapeutic good administrationTherapeutic good administration
Therapeutic good administration
 
Ocular drug delivery system
Ocular drug delivery systemOcular drug delivery system
Ocular drug delivery system
 
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
New Drug Application(Nda) Vs Abbreviated New Drug Application (Anda)
 
Data integrity
Data integrityData integrity
Data integrity
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
European Union
European UnionEuropean Union
European Union
 
ocular drug delivery systems
ocular drug delivery systemsocular drug delivery systems
ocular drug delivery systems
 

Similar a MHRA Data Integrity Requirements

US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
GMP EDUCATION : Not for Profit Organization
 

Similar a MHRA Data Integrity Requirements (20)

WHO Data Integrity Requirements.
WHO Data Integrity Requirements.WHO Data Integrity Requirements.
WHO Data Integrity Requirements.
 
Good Practices for Computerised Systems : PIC/S Guidance
Good Practices for Computerised Systems : PIC/S GuidanceGood Practices for Computerised Systems : PIC/S Guidance
Good Practices for Computerised Systems : PIC/S Guidance
 
US FDA Process Validation Stage 3: Continued Process Verification
US FDA Process Validation Stage 3: Continued Process VerificationUS FDA Process Validation Stage 3: Continued Process Verification
US FDA Process Validation Stage 3: Continued Process Verification
 
Quick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data IntegrityQuick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data Integrity
 
Data Goverance Planning
Data Goverance PlanningData Goverance Planning
Data Goverance Planning
 
Computer System Validation
Computer System ValidationComputer System Validation
Computer System Validation
 
Data Integrity in a GxP-regulated Environment - Pauwels Consulting Academy
Data Integrity in a GxP-regulated Environment - Pauwels Consulting AcademyData Integrity in a GxP-regulated Environment - Pauwels Consulting Academy
Data Integrity in a GxP-regulated Environment - Pauwels Consulting Academy
 
Presentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspectivePresentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspective
 
Data Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLSData Management Plan_Katalyst HLS
Data Management Plan_Katalyst HLS
 
Clinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLSClinical Data Management Plan_Katalyst HLS
Clinical Data Management Plan_Katalyst HLS
 
TGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspectiveTGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspective
 
Data Acquisition Systems | Digilogic Systems
Data Acquisition Systems | Digilogic SystemsData Acquisition Systems | Digilogic Systems
Data Acquisition Systems | Digilogic Systems
 
Data Integrity webinar - Essentials & Solutions
Data Integrity webinar - Essentials & SolutionsData Integrity webinar - Essentials & Solutions
Data Integrity webinar - Essentials & Solutions
 
Maximize Your Understanding of Operational Realities in Manufacturing with Pr...
Maximize Your Understanding of Operational Realities in Manufacturing with Pr...Maximize Your Understanding of Operational Realities in Manufacturing with Pr...
Maximize Your Understanding of Operational Realities in Manufacturing with Pr...
 
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
US FDA Process Validation Stage 2 : No. Of Batches Required for Process Perfo...
 
Process Validation of Legacy Products
Process Validation of Legacy ProductsProcess Validation of Legacy Products
Process Validation of Legacy Products
 
Data Integrity
Data IntegrityData Integrity
Data Integrity
 
Quality Metrics
Quality MetricsQuality Metrics
Quality Metrics
 
Phụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tínhPhụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tính
 
Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016
 

Más de GMP EDUCATION : Not for Profit Organization

Más de GMP EDUCATION : Not for Profit Organization (20)

Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.Risk Assessment for Control of Elemental Impurities.
Risk Assessment for Control of Elemental Impurities.
 
Pharmaceutical Quality System
Pharmaceutical Quality System Pharmaceutical Quality System
Pharmaceutical Quality System
 
New WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method ValidationNew WHO Guidance on Analytical Method Validation
New WHO Guidance on Analytical Method Validation
 
Blend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way ForwardBlend and Content Uniformity : Industry Recommendations for Way Forward
Blend and Content Uniformity : Industry Recommendations for Way Forward
 
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
Content Uniformity and Blend Uniformity : Why FDA Withdrew the 2002 Guidance
 
WHO Guidance on Preparation of Laboratory Information File
WHO  Guidance on Preparation of Laboratory Information FileWHO  Guidance on Preparation of Laboratory Information File
WHO Guidance on Preparation of Laboratory Information File
 
US FDA Quality Metrics Technical Conformance Guide
US FDA  Quality Metrics Technical  Conformance GuideUS FDA  Quality Metrics Technical  Conformance Guide
US FDA Quality Metrics Technical Conformance Guide
 
Calculation of Risk Priority Numbar
Calculation of  Risk Priority NumbarCalculation of  Risk Priority Numbar
Calculation of Risk Priority Numbar
 
New WHO Guidance on CS Validation
New WHO Guidance on CS ValidationNew WHO Guidance on CS Validation
New WHO Guidance on CS Validation
 
ASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and QualificationsASTM Standard E 2500 for Commissioning and Qualifications
ASTM Standard E 2500 for Commissioning and Qualifications
 
US FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ BatchesUS FDA - EU Process Validation : Determination of Number of PPQ Batches
US FDA - EU Process Validation : Determination of Number of PPQ Batches
 
Quality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental MonitoringQuality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental Monitoring
 
Understanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room ContaminationUnderstanding and Preventing Clean Room Contamination
Understanding and Preventing Clean Room Contamination
 
WHO Guidance on Technology Transfers
WHO Guidance on Technology TransfersWHO Guidance on Technology Transfers
WHO Guidance on Technology Transfers
 
Who Guidelines for Preparing SMF
Who Guidelines for Preparing  SMFWho Guidelines for Preparing  SMF
Who Guidelines for Preparing SMF
 
Validation of Microbiological Methods
Validation of Microbiological MethodsValidation of Microbiological Methods
Validation of Microbiological Methods
 
Presentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QPPresentation on EU GMP Annex 16 - Certification by QP
Presentation on EU GMP Annex 16 - Certification by QP
 
WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.WHO Good Practices for Microbiology Labs.
WHO Good Practices for Microbiology Labs.
 
Who Guidance on Quality Risk Management
Who Guidance on Quality Risk ManagementWho Guidance on Quality Risk Management
Who Guidance on Quality Risk Management
 
Water for Pharmaceutical Purposes - New USP Requriements
Water for Pharmaceutical Purposes - New USP  RequriementsWater for Pharmaceutical Purposes - New USP  Requriements
Water for Pharmaceutical Purposes - New USP Requriements
 

MHRA Data Integrity Requirements

  • 1. This presentation is compiled by “ Drug Regulations” a non profit organization which provides free online resource to the Pharmaceutical Professional. Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals. 3/28/2015 1
  • 2. This presentation is compiled from freely available resources like the website of MHRA , specifically “MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015” “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional. Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals. 3/28/2015 2 Drug Regulations : Online Resource for Latest Information
  • 3.  Data integrity ◦ Fundamental in a pharmaceutical quality system ◦ Ensures that medicines are of required quality ◦ This presentation is based on MHRA Guidance ◦ Provides MHRA expectations ◦ Guidance complements existing EU GMP relating to active substances and dosage forms ◦ To be used in conjunction with national medicines legislation and the GMP standards published in Eudralex volume 4. 3/28/2015 3Drug Regulations : Online Resource for Latest Information
  • 4.  Make data governance integral part of pharmaceutical quality system  Provide resources commensurate with the risk to product quality  Forensic approach to data checking is not required on routine basis  Design and operate a system which provides an acceptable state of control  This should be based on the data integrity risk  Document with supporting rationale 3/28/2015 4Drug Regulations : Online Resource for Latest Information
  • 5.  Data integrity requirements apply equally to manual (paper) and electronic data.  Do not revert from automated / computerised to manual / paper-based systems  This will not remove the need for data integrity controls. 3/28/2015 5Drug Regulations : Online Resource for Latest Information
  • 6.  If you do this  It may also constitute a failure to comply with Article 23 of Directive 2001/83/EC,  This article requires an authorisation holder to take account of ◦ Scientific and technical progress and ◦ Enable the medicinal product to be manufactured and checked by means of generally accepted scientific methods. 3/28/2015 6Drug Regulations : Online Resource for Latest Information
  • 7.  Have an overarching data governance system  Include relevant policies and staff training including the importance of data integrity  Consider the organisational (e.g. procedures) controls applied to quality systems  Consider technical (e.g. computer system access) controls applied to quality systems  Ensure that resources applied are commensurate with impact to product quality attributes. 3/28/2015 7Drug Regulations : Online Resource for Latest Information
  • 8.  Data may be generated by ◦ A paper-based record of a manual observation ◦ Equipment or computerized  A spectrum of simple machines  From complex highly configurable computerised systems. 3/28/2015 8Drug Regulations : Online Resource for Latest Information
  • 9.  Inherent data integrity risk ◦ Depends upon the extent to which system generating or using the data can be configured ◦ These systems can be potentially manipulated  See next figure 3/28/2015 9Drug Regulations : Online Resource for Latest Information
  • 10. Diagram to illustrate the spectrum of simple machine (left) to complex computerised system (right), and Relevance of printouts as ‘original data’ 3/28/2015 10Drug Regulations : Online Resource for Latest Information
  • 11.  Simple systems ◦ pH meters and balances ◦ May only require calibration  Complex systems ◦ Require ‘validation for intended purpose’.  Validation effort increases from left to right in the diagram above. 3/28/2015 11Drug Regulations : Online Resource for Latest Information
  • 12.  Systems of apparent lower complexity may be overlooked ◦ Possible to manipulate data ◦ Repeat testing to achieve a desired outcome possible ◦ Limited opportunity of detection  Stand-alone systems with a user configurable output such as FT-IR, UV spectrophotometers 3/28/2015 12Drug Regulations : Online Resource for Latest Information
  • 13.  Design systems to encourage compliance with the principles of data integrity. Ensure ◦ Access to clocks for recording timed events ◦ Accessibility to batch records at locations where activities take place so that ad hoc data recording and later transcription to official records is not necessary ◦ Control over blank paper templates for data recording ◦ User access rights which prevent (or audit trail) data amendments 3/28/2015 13Drug Regulations : Online Resource for Latest Information
  • 14.  Design systems to encourage compliance with the principles of data integrity. Ensure ◦ Automated data capture or printers are attached to equipment such as balances ◦ Proximity of printers to relevant activities ◦ Access to sampling points (e.g. for water systems) ◦ Access to raw data for staff performing data checking activities. 3/28/2015 14Drug Regulations : Online Resource for Latest Information
  • 15.  Use of scribes ◦ May be used to record activity on behalf of another operator ◦ Exceptional ◦ May be used only under following circumstances  Act of recording places the product or activity at risk  e.g. documenting line interventions by sterile operators. ◦ To accommodate cultural or staff literacy / language limitations  Where an activity is performed by an operator, but witnessed and recorded by a Supervisor or Officer. 3/28/2015 15 Drug Regulations : Online Resource for Latest Information
  • 16.  Use of scribes ◦ In both situations,  Supervisory recording must be contemporaneous with the task being performed  Must identify both the person performing the observed task and the person completing the record. 3/28/2015 16 Drug Regulations : Online Resource for Latest Information
  • 17.  Use of scribes ◦ In both situations,  The person performing the observed task should countersign the record wherever possible,  although it is accepted that this countersigning step will be retrospective.  Describe supervisory (scribe) documentation completion in an approved procedure  Specify the activities to which the process applies 3/28/2015 17 Drug Regulations : Online Resource for Latest Information
  • 18. Term Data Definition Information derived or obtained from raw data (e.g. a reported analytical result) Expectation or Guidance Data must be: A - attributable to the person generating the data L – legible and permanent C – contemporaneous O – original record (or ‘true copy’) A - accurate 3/28/2015 18 Drug Regulations : Online Resource for Latest Information
  • 19. Term Raw data Definition • Original records and documentation, retained in the format in which they were originally generated (i.e. paper or electronic), or as a ‘true copy’. • Raw data must be contemporaneously and accurately recorded by permanent means. • In the case of basic electronic equipment which does not store electronic data, or provides only a printed data output (e.g. balance or pH meter), the printout constitutes the raw data. Expectation or Guidance Raw data must: • Be legible and accessible throughout the data lifecycle. • Permit the full reconstruction of the activities resulting in the generation of the data 3/28/2015 19 Drug Regulations : Online Resource for Latest Information
  • 20. Term Metadata: Definition • Data that describes the attributes of other data, and provide context and meaning. • Typically, these are data that describe the structure, data elements, interrelationships and other characteristics of data. • Permits data to be attributable to an individual. Expectation or Guidance Example: • Data : e.g. 3.5 • Metadata, giving context and meaning, are: • sodium chloride batch 1234, 3.5mg. J Smith 01/07/14 • Metadata forms an integral part of the original record. • Without metadata, the data has no meaning. 3/28/2015 20 Drug Regulations : Online Resource for Latest Information
  • 21. Term Data Integrity Definition The extent to which all data are • Complete • Consistent • Accurate throughout the data lifecycle. Expectation or Guidance Data integrity arrangements must ensure that the • Accuracy • Completeness • Content meaning of data is retained throughout the data lifecycle. 3/28/2015 21 Drug Regulations : Online Resource for Latest Information
  • 22. Term Data governance Definition The sum total of arrangements to ensure that data, irrespective of the format in which it is generated, is recorded, processed, retained and used to ensure a complete, consistent and accurate record throughout the data lifecycle Expectation or Guidance Data governance should address • Data ownership throughout the lifecycle • Design, operation and monitoring of processes / systems in order to comply with the principles of data integrity • Control over intentional and unintentional changes to information. 3/28/2015 22 Drug Regulations : Online Resource for Latest Information
  • 23. Term Data governance Expectation or Guidance Data Governance systems should include • Staff training in the importance of data integrity principles • Creation of a working environment that encourages an open reporting culture for errors, omissions and aberrant results. Senior management should be responsible for • Implementation of systems and procedures to minimise the potential risk to data integrity • Identifying the residual risk, using the principles of ICH Q9. • Contract givers to perform a similar review as part of their vendor assurance programme 3/28/2015 23 Drug Regulations : Online Resource for Latest Information
  • 24. Term Data Lifecycle Definition • All phases in the life of the data • Including raw data • From initial generation and recording through processing (including transformation or migration), use, data retention, archive / retrieval and destruction. Expectation or Guidance • Procedures for destruction should consider data criticality and legislative retention requirements. • Archival arrangements should be in place for long term retention • Some cases, periods up to 30 years) for records such as batch documents, marketing authorisation application data, traceability data for human-derived starting materials (not an exhaustive list). • Additionally, at least 2 years of data must be retrievable in a timely manner for the purposes of regulatory inspection. 3/28/2015 24 Drug Regulations : Online Resource for Latest Information
  • 25. Term Primary Record Definition • The record which takes primacy in cases where data that are collected and retained concurrently by more than one method fail to concur. Expectation or Guidance • In situations where the same information is recorded concurrently by more than one system, the data owner should define which system generates and retains the primary record, in case of discrepancy. • The ‘primary record’ attribute should be defined in the quality system • Attribute should not be changed on a case by case basis. 3/28/2015 25 Drug Regulations : Online Resource for Latest Information
  • 26. Term Primary Record Expectation or Guidance • Use Risk management principles to ensure that the assigned ‘primary record’ provides the greatest accuracy, completeness, content and meaning. • Not appropriate for low-resolution or static (printed / manual) data to be designated as a primary record in preference to high resolution or dynamic (electronic) data. • All data should be considered when performing a risk based investigation into data anomalies (e.g. out of specification results) 3/28/2015 26 Drug Regulations : Online Resource for Latest Information
  • 27. Term Original record / True Copy: Definition • Original record: • Data as the file or format in which it was originally generated, preserving the integrity (accuracy, completeness, content and meaning) of the record, • e.g. original paper record of manual observation, or electronic raw data file from a computerised system • True Copy: • An exact verified copy of an original record. • Data may be static (e.g. a ‘fixed’ record such as paper or pdf) or • Dynamic (e.g. an electronic record which the user / reviewer can interact with). 3/28/2015 27 Drug Regulations : Online Resource for Latest Information
  • 28. Term Original record / True Copy: Definition • Example 1: • A group of still images (photographs – the static ‘paper copy’ example) may not provide the full content and meaning of the same event as a recorded moving image (video – the dynamic ‘electronic record’ example). 3/28/2015 28 Drug Regulations : Online Resource for Latest Information
  • 29. Term Original record / True Copy: Definition • Example 2: • Once printed or converted to static .pdfs, chromatography records lose the capability of being reprocessed • Do not enable more detailed viewing of baselines or any hidden fields. • By comparison, the same dynamic electronic records in database format provides the ability to track, trend, and query data, • Allows the reviewer (with proper access permissions) to reprocess, view hidden fields, and expand the baseline to view the integration more clearly. 3/28/2015 29 Drug Regulations : Online Resource for Latest Information
  • 30. Term Original record / True Copy: Expectation or Guidance • Original records and true copies must preserve the integrity (accuracy, completeness, content and meaning) of the record. • Exact (true) copies of original records may be retained in place of the original record (e.g. scan of a paper record), • Put in place a documented system to verify and record the integrity of the copy. 3/28/2015 30 Drug Regulations : Online Resource for Latest Information
  • 31. Term Original record / True Copy: Expectation or Guidance • Raw data generated by electronic means may be retained in an acceptable paper or pdf format. For this 1. Justify how a static record maintains the integrity of the original data. 2. Data retention process must be shown to include • Verified copies of all raw data, metadata, relevant audit trail and result files, • Software / system configuration settings specific to each analytical run*, and • All data processing runs (including methods and audit trails) necessary for reconstruction of a given raw data set. 3/28/2015 31 Drug Regulations : Online Resource for Latest Information
  • 32. Term Original record / True Copy: Expectation or Guidance • Raw data generated by electronic means may be retained in an acceptable paper or pdf format. For this 3. Ensure a documented means to verify that the printed records were an accurate representation. • Onerous approach in its administration to enable a GMP compliant record. • Many electronic records are important to retain in their dynamic (electronic) format, to enable interaction with the data. • Data must be retained in a dynamic form where this is critical to its integrity or later verification. • This should be justified based on risk. 3/28/2015 32 Drug Regulations : Online Resource for Latest Information
  • 33. Term Original record / True Copy: Expectation or Guidance • Define , test , lock & protect computerised system configuration settings from unauthorised access as part of computer system validation. • Only those variable settings which relate to an analytical run would be considered as electronic raw data. 3/28/2015 33 Drug Regulations : Online Resource for Latest Information
  • 34. Term Computer system transactions: Definition • A computer system transaction is 1. A single operation or 2. Sequence of operations performed as a single logical ‘unit of work’. • The operation(s) that make up a transaction may not be saved as a permanent record on durable storage until 1. User commits the transaction through a deliberate act (e.g. pressing a save button), or 2. The system forces the saving of data • The metadata (i.e., user name, date, and time) is not captured in the system audit trail until the user commits the transaction. 3/28/2015 34 Drug Regulations : Online Resource for Latest Information
  • 35. Term Computer system transactions: Definition • In Manufacturing Execution Systems (MES), an electronic signature is often required by the system in order for the record to be saved and become permanent. 3/28/2015 35 Drug Regulations : Online Resource for Latest Information
  • 36. Term Computer system transactions: Expectation or Guidance • Computer systems should be designed to ensure that 1. Execution of critical operations are recorded contemporaneously by the user 2. Not combined into a single computer system transaction with other operations. 3. A critical processing step is a parameter that must be within an appropriate limit, range, or distribution to ensure the desired product quality. 4. These should be reflected in the process control strategy. 3/28/2015 36 Drug Regulations : Online Resource for Latest Information
  • 37. Term Computer system transactions: Expectation or Guidance • Examples of 'units of work': 1. Weighing of individual materials 2. Entry of process critical manufacturing / analytical parameters 3. Verification of the identity of each component or material that will be used in a batch 3/28/2015 37 Drug Regulations : Online Resource for Latest Information
  • 38. Term Computer system transactions: Expectation or Guidance 4. Verification of the addition of each individual raw material to a batch (e.g. when the sequence of addition is considered critical to process control 3/28/2015 38 Drug Regulations : Online Resource for Latest Information
  • 39. Term Computer system transactions: Expectation or Guidance 5. Addition of multiple pre-weighed raw materials to bulk vessel when required as a single manufacturing step (e.g. when the sequence of addition is not considered critical to process control 3/28/2015 39 Drug Regulations : Online Resource for Latest Information
  • 40. Term Audit Trail Definition • GMP audit trails are metadata that are a record of GMP critical information • (for example the change or deletion of GMP relevant data), • They permit the reconstruction of GMP activities. Expectation or Guidance • Where computerised systems are used to capture, process, report or store raw data electronically System design should 1. Always provide for the retention of full audit trails to show all changes to the data 2. Retain previous and original data. 3. Associate all changes to data with the persons making those changes, 4. Time stamp changes 5. Have a facility to Provide reason for change. 6. Not provide users the facility to amend or switch off the audit trail. 40
  • 41. Term Audit Trail Expectation or Guidance • Consider relevance of data retained in audit trails • This should permit robust data review / verification. • Should permit reconstruction of the process or activity. • No need to include every system activity (e.g. user log on/off, keystrokes etc.) in audit trail • This may be achieved by review of designed and validated system reports. 3/28/2015 41 Drug Regulations : Online Resource for Latest Information
  • 42. Term Audit Trail Expectation or Guidance • Audit trail review 1. Part of the routine data review / approval process 2. Performed by the operational area which has generated the data (e.g. laboratory). 3. Evidence to confirm that review of the relevant audit trails have taken place. 4. Limited to those with GMP relevance (e.g. relating to data creation, processing, modification and deletion etc). 5. Reviewed as a list of relevant data, or by a validated ‘exception reporting’ process. 6. Sample audit trail, raw data and metadata reviewed by QA to ensure ongoing compliance 3/28/2015 42 Drug Regulations : Online Resource for Latest Information
  • 43. Term Audit Trail Expectation or Guidance • System without audit trail 1. Have a paper based audit trail 2. Capable of demonstrating changes to data 3. Permitted until a fully audit trailed system becomes available. 4. Permitted, where they achieve equivalence to integrated audit trail described in Annex 11 of the GMP Guide. 5. If equivalence cannot be demonstrated, it is expected that facilities should upgrade to an audit trailed system by the end of 2017. 3/28/2015 43 Drug Regulations : Online Resource for Latest Information
  • 44. Term Data Review Definition • Implement a procedure for review and approval of data, including raw data. • Include review of relevant metadata, data , including audit trail. Expectation or Guidance Document Data Review • Action to be taken if data review identifies an error or omission should be specified in a procedure. • Procedure should enable data corrections or clarifications to be made in a GMP compliant manner • Original record should be visible and audit trailed using ALCOA principle 3/28/2015 44 Drug Regulations : Online Resource for Latest Information
  • 45. Term Computerised system user access / system administrator roles Expectation or Guidance Make full use of access controls 1. Ensure that people have access only to functionality that is appropriate for their job role 2. Actions should be attributable to a specific individual 3. Demonstrate different access levels granted to individual staff members 4. Ensure that historical information regarding user access level is available 5. Do not use shared logins or generic user access 6. Where the computerised system design supports individual user access, this function must be used. 7. This may require the purchase of additional licences. 3/28/2015 45 Drug Regulations : Online Resource for Latest Information
  • 46. Term Computerised system user access / system administrator roles Expectation or Guidance 8. Some computerised systems support only a single user login or limited numbers of user logins. 9. Upgrade to an appropriate system by the end of 2017 where unique login is feasible. 10. Where no suitable alternative computerised system is available, a paper based method of providing traceability is permitted. 11. Justify & document the suitability of alternate system based on a review of system design, and documented. 3/28/2015 46 Drug Regulations : Online Resource for Latest Information
  • 47. Term Computerised system user access / system administrator roles Expectation or Guidance 12.Restrict system administrator access to the minimum number of people possible 13.Consider the size and nature of the organisation for this. 14.Generic system administrator account should not be available for use. 15. Personnel with system administrator access should log in under unique log-ins 16.Ensure that all actions in the audit trail(s) are attributed to a specific individual. 3/28/2015 47 Drug Regulations : Online Resource for Latest Information
  • 48. Term Computerised system user access / system administrator roles Expectation or Guidance 17.Ensure that individual logs- in using account with appropriate access rights for the given task • Manager performing data checking should not log in as system administrator • System admistrator will have a more appropriate level of access for that task. 3/28/2015 48 Drug Regulations : Online Resource for Latest Information
  • 49. Term Data retention Definition • Raw data generated in paper format may be retained for example by scanning • For copies there should be a process in place to ensure that the copy is verified to ensure its completeness. • Data retention may be classified as archive or backup Expectation or Guidance • Protect the records from deliberate or inadvertent alteration or loss during retention. • Place secure controls in place to ensure data Integrity of the record throughout the retention period. • Validate where appropriate. 3/28/2015 49 Drug Regulations : Online Resource for Latest Information
  • 50. Term Data retention Expectation or Guidance • Contracted Data Retention 1. Specify the ownership and retrieval of data held under this arrangement. 2. Consider physical location in which the data is held 3. Consider impact of any local laws applicable 4. Define responsibilities of the contract giver and acceptor as described in Chapter 7 of the GMP Guide 3/28/2015 50 Drug Regulations : Online Resource for Latest Information
  • 51. Term Archive Definition • Long term, permanent retention of completed data and relevant metadata in its final form for the purposes of reconstruction of the process or activity. Expectation or Guidance • Lock records such that they cannot be altered or deleted without detection and audit trail. • Archive must permit recovery and readability of the data and metadata throughout the required retention period. 3/28/2015 51 Drug Regulations : Online Resource for Latest Information
  • 52. Term Backup Definition • A copy of current (editable) data, metadata and system configuration settings (variable settings which relate to an analytical run) maintained for the purpose of disaster recovery. Expectation or Guidance • Backup and recovery processes must be validated 3/28/2015 52 Drug Regulations : Online Resource for Latest Information
  • 53. Term File structure Expectation or Guidance • File structure has a significant impact on the inherent data integrity risks. • The ability to manipulate or delete flat files requires a higher level of logical and procedural control over data generation, review and storage. 3/28/2015 53 Drug Regulations : Online Resource for Latest Information
  • 54. Term Flat files: Definition • A 'flat file' is an individual record which may not carry with it all relevant metadata (e.g. pdf, dat, doc ). Expectation or Guidance • Flat files may carry basic metadata relating to file creation and date of last amendment, • However they may not audit trail the type and sequence of amendments. • When creating flat file reports from electronic data, the metadata and audit trails relating to the generation of the raw data may be lost, unless these are retained as a ‘true copy’. 3/28/2015 54 Drug Regulations : Online Resource for Latest Information
  • 55. Term Flat files: Expectation or Guidance • Consideration also needs to be given to the ‘dynamic’ nature of the data, where appropriate (see ‘true copy’ definition) • There is an inherently greater data integrity risk with flat files (e.g. when compared to data contained within a relational database), in that these are easier to manipulate and delete as a single file. 3/28/2015 55 Drug Regulations : Online Resource for Latest Information
  • 56. Term Relational database: Definition • A relational database stores different components of associated data and metadata in different places. • Each individual record is created and retrieved by compiling the data and metadata for review Expectation or Guidance • File structure is inherently more secure • Data is held in a large file format • Preserves the relationship between data and metadata. • More resilient to attempts to selectively delete, amend or recreate data and the metadata trail of actions, compared to a flat file system. • Retrieval of information requires a database search tool, or the original application which created the record. 3/28/2015 56 Drug Regulations : Online Resource for Latest Information
  • 57. Term Validation - for intended purpose (See also Annex 15 and GAMP 5) Expectation or Guidance • Computerised systems 1. Must comply with the requirements of EU GMP Annex 11 2. Be validated for their intended purpose. 3. Understand the computerised system's function within a process. 4. Acceptance of vendor-supplied validation data in isolation of system configuration and intended use is not acceptable. 5. In isolation from the intended process or end user IT infrastructure, vendor testing is likely to be limited to functional verification only 6. This may not fulfil the requirements for performance qualification. 3/28/2015 57 Drug Regulations : Online Resource for Latest Information
  • 58. Term Validation - for intended purpose (See also Annex 15 and GAMP 5) Expectation or Guidance For example – validation of computerised system audit trail • A custom report generated from a relational database may be used as a GMP system audit trail. • SOPs should be drafted during OQ to describe the process for audit trail verification, including definition of the data to be reviewed. • 'Validation for intended use' would include testing during PQ to confirm that the required data is correctly extracted by the custom report, and presented in a manner which is aligned with the data review process described in the SOP. 3/28/2015 58 Drug Regulations : Online Resource for Latest Information
  • 59. This presentation is compiled from freely available resources like the website of EMA , specifically “MHRA GMP Data Integrity Definitions and Guidance for Industry March 2015” “Drug Regulations” is a non profit organization which provides free online resource to the Pharmaceutical Professional. Visit http://www.drugregulations.org for latest information from the world of Pharmaceuticals. 3/28/2015 59 Drug Regulations : Online Resource for Latest Information